Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Lung Cancer

  Free Subscription


1 Am J Clin Oncol
3 Am J Respir Crit Care Med
3 Ann Oncol
1 Ann Surg Oncol
2 Ann Thorac Surg
1 Anticancer Res
1 BMC Cancer
2 Br J Cancer
1 Cancer Cell
2 Cancer Lett
1 Cancer Res
1 Cancer Sci
1 Clin Exp Metastasis
3 Clin Lung Cancer
2 Eur J Cancer
1 Hum Pathol
1 Int J Cancer
3 J Cancer Res Clin Oncol
1 J Surg Oncol
12 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 JAMA Oncol
11 Lung Cancer
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Oncol

  1. CLAMON G, Zeitler W, An J, Hejleh TA, et al
    Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review.
    Am J Clin Oncol. 2020 Jun 5. doi: 10.1097/COC.0000000000000720.
    PubMed         Abstract available

    Am J Respir Crit Care Med

  2. QUAIFE SL, Ruparel M, Dickson JL, Beeken RJ, et al
    Reply to: Improving Lung Cancer Screening Uptake.
    Am J Respir Crit Care Med. 2020 Jun 11. doi: 10.1164/rccm.202005-1699.

    Improving Lung Cancer Screening Uptake.
    Am J Respir Crit Care Med. 2020 Jun 11. doi: 10.1164/rccm.202004-1486.

    On the Origin of Lung Cancers.
    Am J Respir Crit Care Med. 2020;201:646-647.

    Ann Oncol

    Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2020 Jun 2. pii: S0923-7534(20)39865.

  6. ZHAI H, Moore D, Jamal-Hanjani M
    Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma.
    Ann Oncol. 2020;31:169-170.

  7. MAZZOTTA M, Filetti M, Rossi A, Roberto M, et al
    Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
    Ann Oncol. 2020;31:440-441.

    Ann Surg Oncol

  8. LETICA-KRIEGEL AS, Leinwand JC, Sonett JR, Gorenstein LA, et al
    50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
    Ann Surg Oncol. 2020;27:205-213.
    PubMed         Abstract available

    Ann Thorac Surg

  9. DENLINGER CE, Gibney BC
    Selective Delivery of Adjuvant Chemotherapy to Healthier Patients.
    Ann Thorac Surg. 2020;109:1520-1521.

  10. ZHANG Y, Fu F, Chen H
    Management of ground-glass opacities in the lung cancer spectrum.
    Ann Thorac Surg. 2020 Jun 7. pii: S0003-4975(20)30894.
    PubMed         Abstract available

    Anticancer Res

  11. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed         Abstract available

    BMC Cancer

  12. LIU Y, Zhu Y, Bai L, Chen F, et al
    Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.
    BMC Cancer. 2020;20:520.
    PubMed         Abstract available

    Br J Cancer

  13. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed         Abstract available

  14. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed         Abstract available

    Cancer Cell

  15. COLES GL, Cristea S, Webber JT, Levin RS, et al
    Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
    Cancer Cell. 2020 May 22. pii: S1535-6108(20)30253.
    PubMed         Abstract available

    Cancer Lett

  16. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed         Abstract available

  17. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed         Abstract available

    Cancer Res

  18. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed         Abstract available

    Cancer Sci

  19. DENG M, Liu B, Zhang Z, Chen Y, et al
    The knockdown of GPSM2 promotes the metastasis of non-small cell lung cancer by inducing the expression of Snail.
    Cancer Sci. 2020 Jun 10. doi: 10.1111/cas.14519.
    PubMed         Abstract available

    Clin Exp Metastasis

  20. REDDY SP, Dowell JE, Pan E
    Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients.
    Clin Exp Metastasis. 2020 Jun 4. pii: 10.1007/s10585-020-10040.
    PubMed         Abstract available

    Clin Lung Cancer

  21. FRIEDLAENDER A, Liu SV, Passaro A, Metro G, et al
    The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Apr 30. pii: S1525-7304(20)30105.
    PubMed         Abstract available

  22. MARMARELIS ME, Langer CJ
    Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30010.
    PubMed         Abstract available

  23. GUERINI AE, Borghetti P, Filippi AR, Bonu ML, et al
    Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30167.

    Eur J Cancer

  24. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed         Abstract available

  25. SADATE A, Occean BV, Beregi JP, Hamard A, et al
    Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography.
    Eur J Cancer. 2020;134:107-114.
    PubMed         Abstract available

    Hum Pathol

  26. BUTNOR KJ, Pavlisko EN, Sporn TA, Roggli VL, et al
    Mesothelioma of the tunica vaginalis testis.
    Hum Pathol. 2019 Jul 31. pii: S0046-8177(19)30133.
    PubMed         Abstract available

    Int J Cancer

  27. VELAZQUEZ-KRONEN R, Gilbert ES, Linet MS, Moysich KB, et al
    Lung cancer mortality associated with protracted low-dose occupational radiation exposures and smoking behaviors in U.S. radiologic technologists, 1983-2012.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33141.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  28. WEN Z, Zhao Y, Fu F, Hu H, et al
    Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter.
    J Cancer Res Clin Oncol. 2020;146:1603-1613.
    PubMed         Abstract available

  29. ZHAO M, Chen Z, Zheng Y, Liang J, et al
    Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
    J Cancer Res Clin Oncol. 2020;146:1463-1472.
    PubMed         Abstract available

  30. ZHOU H, Sun Y, Xiu W, Han J, et al
    Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 9. pii: 10.1007/s00432-020-03282.
    PubMed         Abstract available

    J Surg Oncol

  31. GILL RR, Barlow J, Jaklitsch MT, Schmidlin EJ, et al
    Image-guided video-assisted thoracoscopic resection (iVATS): Translation to clinical practice-real-world experience.
    J Surg Oncol. 2020;121:1225-1232.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

    Is ventilatory efficiency the next new thing in prehabilitation?
    J Thorac Cardiovasc Surg. 2020;159:e323-e324.

  33. SESTI J, Paul S
    Commentary: Known unknowns and unknown unknowns: The case of the indeterminate margin.
    J Thorac Cardiovasc Surg. 2020;159:2042.

    Commentary: A journey of a thousand miles begins with a single step.
    J Thorac Cardiovasc Surg. 2020;159:2092-2093.

  35. PASS HI
    Commentary: Not only SMART clinically, but translationally!
    J Thorac Cardiovasc Surg. 2020;159:2094-2095.

    Commentary: Is thoracic cage volume a new parameter for clinical staging in mesothelioma?
    J Thorac Cardiovasc Surg. 2020;159:2520-2521.

  37. BOFFA DJ, Salazar M
    Commentary: How surprising.
    J Thorac Cardiovasc Surg. 2020;159:2483-2484.

    Commentary: The power of indeterminacy.
    J Thorac Cardiovasc Surg. 2020;159:2041.

    Commentary: Why do uniportal video-assisted thoracoscopic lobectomy?
    J Thorac Cardiovasc Surg. 2020;159:2496-2497.

  40. HOANG CD
    Commentary: Surgeon versus mesothelioma in a thoracic cage match.
    J Thorac Cardiovasc Surg. 2020;159:2522-2523.

  41. GILES AE, Kidane B
    Commentary: Know your enemy-Understanding futility in the battle against malignant pleural mesothelioma.
    J Thorac Cardiovasc Surg. 2020;159:2523-2524.

    Commentary: Durable activity of a tyrosine kinase inhibitor in lung cancer.
    J Thorac Cardiovasc Surg. 2020 Apr 23. pii: S0022-5223(20)30985.

  43. HOANG CD
    Commentary: Smoke or fire? Resected lung cancer in never-smokers.
    J Thorac Cardiovasc Surg. 2020 Apr 10. pii: S0022-5223(20)30795.

    J Thorac Oncol

  44. UPRETY D, Mandrekar SJ, Wigle D, Roden AC, et al
    Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.
    J Thorac Oncol. 2020 Jun 6. pii: S1556-0864(20)30425.
    PubMed         Abstract available

    JAMA Oncol

  45. KAS B, Talbot H, Ferrara R, Richard C, et al
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 11. pii: 2766806. doi: 10.1001/jamaoncol.2020.1634.
    PubMed         Abstract available

    Lung Cancer

  46. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed         Abstract available

  47. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed         Abstract available

  48. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed         Abstract available

  49. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed         Abstract available

  50. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed         Abstract available

  51. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed         Abstract available

  52. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed         Abstract available

  53. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed         Abstract available

  54. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed         Abstract available

  55. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed         Abstract available

  56. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed         Abstract available

    PLoS One

  57. LI B, Dai C, Wang L, Deng H, et al
    A novel drug repurposing approach for non-small cell lung cancer using deep learning.
    PLoS One. 2020;15:e0233112.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.